Chemomab Therapeutics (CMMB) Depreciation & Amortization (CF) (2018 - 2023)
Chemomab Therapeutics (CMMB) posted Depreciation & Amortization (CF) of $16000.0 for Q4 2023, down 15.79% on a QoQ basis from $19000.0 in Q3 2023, and up 14.29% year-over-year from $14000.0 in Q4 2022.
Chemomab Therapeutics (CMMB) Depreciation & Amortization (CF) (2018 - 2023) Analysis & Trends
Chemomab Therapeutics' Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $16000.0 for Q4 2023.
- Quarterly Depreciation & Amortization (CF) rose 14.29% year-over-year to $16000.0 in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $16000.0 (down 75.38% YoY) and the FY2025 annual result came in at $70000.0, up 32.08% from the prior year.
- Depreciation & Amortization (CF) was $16000.0 for Q4 2023 at Chemomab Therapeutics, down from $19000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $211000.0 in Q4 2019 and bottomed at $5000.0 in Q1 2020.
- A 5-year average of $23200.0 and a median of $14000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2019 — Depreciation & Amortization (CF) soared 955.0% — and 2020, when it plunged 97.16%.
- Chemomab Therapeutics' Depreciation & Amortization (CF) stood at $211000.0 in 2019, then plunged by 97.16% to $6000.0 in 2020, then jumped by 83.33% to $11000.0 in 2021, then increased by 27.27% to $14000.0 in 2022, then gained by 14.29% to $16000.0 in 2023.
- Business Quant data shows CMMB's Depreciation & Amortization (CF) at $16000.0 in Q4 2023, $19000.0 in Q3 2023, and $16000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 16,000.00 |
| Dec 31, 2023 | 16,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Jun 30, 2023 | 16,000.00 |
| Jun 30, 2023 | 16,000.00 |
| Mar 31, 2023 | 16,000.00 |
| Mar 31, 2023 | 16,000.00 |
| Dec 31, 2022 | 14,000.00 |
| Dec 31, 2022 | 14,000.00 |
| Sep 30, 2022 | 17,000.00 |
| Sep 30, 2022 | 17,000.00 |
| Jun 30, 2022 | 14,000.00 |
| Jun 30, 2022 | 14,000.00 |
| Mar 31, 2022 | 13,000.00 |
| Mar 31, 2022 | 13,000.00 |
| Dec 31, 2021 | 11,000.00 |
| Dec 31, 2021 | 11,000.00 |
| Sep 30, 2021 | 9,000.00 |
| Sep 30, 2021 | 9,000.00 |